Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Warner Chilcott
The comparator arms of this risedronate study are 35 mg delayed release given weekly and 5 mg immediate release given daily.
Age
50–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female: 50 years of age or older
\>5 years since last menses natural or surgical
have lumbar spine or total hip BMD more that 2.5 SD below the young adult mean, or have lumbar spine or total hip BMD more than 2.0 SD below the young adult female mean value and also have at least one prevalent vertebral body fracture
You may not be if
history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia
BMI \>32 kg/m
use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone
hypocalcemia or hypercalcemia of any cause
markedly abnormal clinical laboratory measurements that are assessed as clinically significant by the investigator
Clareo Health | A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
